• Dry Cracked Skin
  • General Dermatology
  • Impetigo
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Weekly Roundup: July 27-31


ICYMI, some of the content featured this week includes results from trials investigating topical minocycline and calcipotriene betamethasone foam. Also, FDA approval of a combination treatment for advanced melanoma, a new picosecond laser, plus more.

In case you missed it, this week we featured articles on topical minocycline being well-tolerated, positive results from a phase 3 calcipotriene betamethasone foam trial, U.S. Food and Drug Administration approval of a combination treatment for advanced melanoma, a new picosecond laser for treatment of pigmentary disorders in darker skin types, plus more.

Calcipotriene betamethasone foam phase 3 trial succeeds

Twice-weekly treatment with calcipotriene-betamethasone diproprionate provides safe and effective maintenance treatment for plaque psoriasis, according to phase 3 data.

The Mainstream Patient: July 27

This week’s edition of The Mainstream Patient features stories about inflammation-linked aging, how to get rid of varicose veins, Kybella for under the chin, plus more.

Aesthetic therapeutics on the horizon

Hema Sundaram, MA, MD, FAAD, highlights an exciting new technology that may change the future of aesthetic therapeutics.

Topical minocycline foam safe, well-tolerated

A topical minocycline foam application appears effective and was well-tolerated by patients with moderate-to-severe papulopustular rosacea.

Long-term benefits of pembrolizumab in melanoma

A recently published pooled 10-year analysis shows pembrolizumab demonstrates long-term survival benefits for advanced melanoma patients regardless of BRAF V600E/K mutation status or history of BRAFi, with or without MEKi therapy.

Probiotics for psoriasis?

Cath O'Niell, chief scientific officer at SkinBioTherapeutics and professor of translational dermatology at the University of Manchester, discusses her recent research on developing probiotics to treat psoriasis and other inflammatory skin diseases.

Pilot study examines facial microbiome diversity

A study in twins highlights exacerbating factors for patients with rosacea and the importance of the microbiome.

FDA expands toxic hand sanitizer list

The FDA expands their list of hand sanitizers found to contain methanol, a toxic chemical, which, when absorbed through the skin or ingested, can lead to adverse events.

Studies examine ingredient safety over lifetime use

Findings of initial studies and call for further testing should not be misconstrued to mean ingredients are unsafe.

New picosecond laser treats pigmentary disorders in darker skin types

The new 730-nm picosecond laser demonstrates strong efficacy and safety in darker skin types for treatment of endogenous pigmentary disorders, according to a recent case study.

Survey findings inform messaging on UV exposure

Findings from a survey of college students examining beliefs about UV exposure and sunscreen use and their associations with skin cancer risk and UV protective behaviors provide some insights for patient counseling.

FDA approves combination treatment for advanced melanoma

The U.S. Food and Drug Administration has approved atezolizumab plus cobimetinib and vemurafenib for treatment of BRAF V600 mutation-positive advanced melanoma. Studies show the combination treatment prolonged patients’ lives by 15 months without disease worsening.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.